Several cancer types show dysregulated expression of complement factor H (CFH). Here the authors report the results of a phase 1b dose escalation trial of GT103, a first-in-class, fully human, IgG3 monoclonal antibody targeting CFH, in patients with refractory NSCLC.
- Jeffrey M. Clarke
- George R. Simon
- Edward F. Patz Jr
